Title:
PHARMACEUTICAL COMPOSITION FOR TREATING DIFFUSE-TYPE GASTRIC CANCER
Document Type and Number:
WIPO Patent Application WO/2020/100969
Kind Code:
A1
Abstract:
The present invention addresses the problem of providing a molecular targeted drug that is efficacious for diffuse-type gastric cancer. Provided is a pharmaceutical composition for treating diffuse-type gastric cancer in a patient, said pharmaceutical composition comprising an EGF receptor inhibitor having ErbB1 inhibitory activity and ErbB4 inhibitory activity. Also provided is the aforesaid pharmaceutical composition that is to be used in a combination therapy with an anti-VEGF receptor 2 antibody and/or a cMET inhibitor. Also provided is a method for treating diffuse-type gastric cancer in a patient, said method comprising a step for administering the patient with an EGF receptor inhibitor having ErbB1 inhibitory activity and ErbB4 inhibitory activity.
More Like This:
Inventors:
YASUMOTO KAZUO (JP)
Application Number:
PCT/JP2019/044662
Publication Date:
May 22, 2020
Filing Date:
November 14, 2019
Export Citation:
Assignee:
KANAZAWA MEDICAL UNIV (JP)
International Classes:
A61K31/506; A61K45/00; A61P35/00
Domestic Patent References:
| WO2017100642A1 | 2017-06-15 | |||
| WO2012131065A1 | 2012-10-04 | |||
| WO2018174053A1 | 2018-09-27 | |||
| WO2018055029A1 | 2018-03-29 |
Foreign References:
| JP2014517259A | 2014-07-17 | |||
| US20060002934A1 | 2006-01-05 | |||
| JP2016516800A | 2016-06-09 | |||
| JP2016515141A | 2016-05-26 |
Other References:
MATEUS, A. R. ET AL.: "E-cadherin mutations and cell motility: A genotype- phenotype correlation.", EXPERIMENTAL CELL RESEARCH, vol. 315, no. 8, 2009, pages 1393 - 1402, XP026041472, DOI: 10.1016/j.yexcr.2009.02.020
J ANJIGIAN,Y.Y. ET AL.: "Establishment of esophagogastric xenografts: A model for characterizing disease heterogeneity.", JOURNAL OF CLINICAL ONCOLOGY, vol. 30, no. 30, 30 November 2011 (2011-11-30), US, pages 95 - 95, XP009528259, ISSN: 0732-183X, DOI: 10.1200/jco.2012.30.30_suppl.95
ZHAO L. ET AL., CANCER SCIENCE, vol. 104, no. 12, December 2013 (2013-12-01), pages 1640 - 1646
YASUMOTO K. ET AL., CLIN. CANCER RES., vol. 17, 2011, pages 3619 - 3630
KOIZUMI W. ET AL., LANCET ONCOL., vol. 9, no. 3, 2008, pages 215 - 21
ZHANG ET AL., JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 7, 2014, pages 22
HUA XIE ET AL., PLOS ONE, vol. 6, no. 7, pages e21487
JAMES WT. YATES ET AL., MOL. CANCER THER., vol. 15, no. 10, 2016, pages 2378 - 87
NICOLAS FLOC'H ET AL., MOL. CANCER THER., vol. 17, no. 5, 2018, pages 885 - 96
CROSS D.A.E. ET AL., CANCER DISCOV., vol. 4, no. 9, September 2014 (2014-09-01), pages 1046 - 1061
MODJTAHEDI H. ET AL., NAUNYN-SCHMIEDEBERG'S ARCH.PHARMACOL., vol. 387, 2014, pages 505 - 52
CHA MY ET AL., INT. J. CANCER, vol. 130, 2012, pages 2445 - 2454
ENGELMAN J.A. ET AL., CANCER RES., vol. 67, no. 24, 2007, pages 11924 - 32
TRAXLER P. ET AL., CANCER RESEARCH, vol. 64, 15 July 2004 (2004-07-15), pages 4931 - 4941
WONG T. W. ET AL., CLIN. CANCER RES., vol. 12, no. 20, 15 October 2006 (2006-10-15)
DOI T. ET AL., BRITISH JOURNAL OF CANCER, vol. 106, 2012, pages 666 - 672
AMEMIYA ET AL., ONCOLOGY, vol. 63, 2002, pages 286 - 96
PARK ET AL., APMIS, vol. 108, 2000, pages 195 - 200
OLAYIOYE MA ET AL., EMBO J., vol. 19, 2000, pages 3159 - 67
NAKASHIO T ET AL., INT. J. CANCER, vol. 70, 1997, pages 612 - 8
NAKAJIMA M. ET AL., CANCER, vol. 85, 1999, pages 1894 - 1902
KALLURI R ET AL., NAT. REV. CANCER, vol. 6, 2006, pages 392 - 401
CAS, no. 1206799-15-6
MODJTAHEDI H. ET AL., NAUNYN-SCHMIEDEBERG'S ARCH. PHARMACOL., vol. 387, 2014, pages 505 - 52
WITTE L. ET AL., CANCER METASTASIS REV., 1998, pages 155 - 161
ISHIYAMA M. ET AL., TALENTA, vol. 44, 1997, pages 1299
See also references of EP 3881847A4
J ANJIGIAN,Y.Y. ET AL.: "Establishment of esophagogastric xenografts: A model for characterizing disease heterogeneity.", JOURNAL OF CLINICAL ONCOLOGY, vol. 30, no. 30, 30 November 2011 (2011-11-30), US, pages 95 - 95, XP009528259, ISSN: 0732-183X, DOI: 10.1200/jco.2012.30.30_suppl.95
ZHAO L. ET AL., CANCER SCIENCE, vol. 104, no. 12, December 2013 (2013-12-01), pages 1640 - 1646
YASUMOTO K. ET AL., CLIN. CANCER RES., vol. 17, 2011, pages 3619 - 3630
KOIZUMI W. ET AL., LANCET ONCOL., vol. 9, no. 3, 2008, pages 215 - 21
ZHANG ET AL., JOURNAL OF HEMATOLOGY & ONCOLOGY, vol. 7, 2014, pages 22
HUA XIE ET AL., PLOS ONE, vol. 6, no. 7, pages e21487
JAMES WT. YATES ET AL., MOL. CANCER THER., vol. 15, no. 10, 2016, pages 2378 - 87
NICOLAS FLOC'H ET AL., MOL. CANCER THER., vol. 17, no. 5, 2018, pages 885 - 96
CROSS D.A.E. ET AL., CANCER DISCOV., vol. 4, no. 9, September 2014 (2014-09-01), pages 1046 - 1061
MODJTAHEDI H. ET AL., NAUNYN-SCHMIEDEBERG'S ARCH.PHARMACOL., vol. 387, 2014, pages 505 - 52
CHA MY ET AL., INT. J. CANCER, vol. 130, 2012, pages 2445 - 2454
ENGELMAN J.A. ET AL., CANCER RES., vol. 67, no. 24, 2007, pages 11924 - 32
TRAXLER P. ET AL., CANCER RESEARCH, vol. 64, 15 July 2004 (2004-07-15), pages 4931 - 4941
WONG T. W. ET AL., CLIN. CANCER RES., vol. 12, no. 20, 15 October 2006 (2006-10-15)
DOI T. ET AL., BRITISH JOURNAL OF CANCER, vol. 106, 2012, pages 666 - 672
AMEMIYA ET AL., ONCOLOGY, vol. 63, 2002, pages 286 - 96
PARK ET AL., APMIS, vol. 108, 2000, pages 195 - 200
OLAYIOYE MA ET AL., EMBO J., vol. 19, 2000, pages 3159 - 67
NAKASHIO T ET AL., INT. J. CANCER, vol. 70, 1997, pages 612 - 8
NAKAJIMA M. ET AL., CANCER, vol. 85, 1999, pages 1894 - 1902
KALLURI R ET AL., NAT. REV. CANCER, vol. 6, 2006, pages 392 - 401
CAS, no. 1206799-15-6
MODJTAHEDI H. ET AL., NAUNYN-SCHMIEDEBERG'S ARCH. PHARMACOL., vol. 387, 2014, pages 505 - 52
WITTE L. ET AL., CANCER METASTASIS REV., 1998, pages 155 - 161
ISHIYAMA M. ET AL., TALENTA, vol. 44, 1997, pages 1299
See also references of EP 3881847A4
Attorney, Agent or Firm:
SIKS & CO. (JP)
Download PDF: